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From its discovery, hepcidin has generated many hopes in terms of diagnosis and man-
agement of a wide variety of iron-related diseases. However, in clinical use its accurate
quantiﬁcation remains a challenge due to the limited sensitivity, speciﬁcity or repro-
ducibility of the techniques described. In this work, we adapted a highly speciﬁc and
quantitative mass spectrometry method based on selected reaction monitoring (SRM) to
measure hepcidin. Our objective was to adapt the feasibility and reproducibility of the
workﬂow to a clinical environment. Analytical validation was performed according to ISO
15189  norms for determining the limit of detection (LOD, 2 ng/mL), limit of quantiﬁcation
(LOQ,  6 ng/mL), repeatability, reproducibility and linearity (up to 200 ng/mL). Using the serum
of  patients with various iron-related diseases we compared our SRM detection method to
the  well-characterized competitive ELISA (cELISA) test. The two methods were commutable
(Bland–Altman plot) and we found a positive and signiﬁcant correlation (r2 = 0.96, Pearson
correlation coefﬁcient p < 0.001) between both methods, although the absolute concentra-
tion determined is different from factor 5. The validation of our SRM method encourages usto  propose it as an alternative approach for accurate determination of hepcidin in human
samples for clinical diagnosis, follow-up and management of iron-related diseases.
© 2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). Open access under CC BY-NC-ND license.Abbreviations: SRM, selected reaction monitoring; ELISA, enzyme-l
acid.
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.  Introduction
epcidin is a 25 amino-acid (aa) cystein-rich peptide involved
n iron metabolism: it regulates both intestinal iron absorp-
ion and macrophage iron recycling. There are several clinical
pplications for hepcidin measurements such as iron overload
isorders and anemia, chronic inﬂammation, kidney disease
nd cancer [1,2]. This peptide can also be found in the 20,
2 and 24-aa isoforms [3]; however the histopathological rel-
vance of these isoforms still needs to be determined and
hey are most likely the result of the degradation of the
ioactive 25-aa isoform. Since 2001 [4–6], various methods
ave been published on accurate quantiﬁcation of hep-
idin [7–9]. Among them, we can mention radio-immuno
ssay (RIA), Enzyme-linked immunosorbent assay (ELISA)
nd more  recently, mass spectrometry analysis (SELDI-TOF
nd LC–MS/MS). Immunoassays are based on the use of
nti-hepcidin antibodies (therefore potentially identifying the
ifferent isoforms) and mass spectrometric approaches to
peciﬁcally detect the different types of hepcidin. Further-
ore,  absolute quantitation is possible through normalization
ia a spiked internal standard of hepcidin. These methods
ave their limits, especially in regards to speciﬁcity (for the 25
a-isoform) and assay reproducibility for repetitive quantiﬁ-
ation of a same sample. In addition, the different approaches
iffer greatly in terms of absolute values of hepcidin. These
iscrepancies are speciﬁcally related to the inherent prop-
rties of the peptide’s structure, its low immunogenicity, its
ropensity to aggregate as well as the existence of smaller iso-
orms, which could affect the immunochemical assay results.
owever, the various studies comparing these approaches
ave reported a good correlation between the different meth-
ds [7,8].
Recently and in order to standardize the quantitation of
epcidin, different methods have been compared via inter-
aboratory studies [7,8]. These studies have underlined the
hallenges in developing a reliable assay and recommended
he use of internal standards for MS-based methods, using a
alibrator mimicking human serum and setting a consensus
n calibrator levels.
We  have developed a nano-liquid chromatography
andem-mass spectrometry (LC–MS/MS) to reliably quantify
epcidin-25 in human serum. Nano-LC system are generally
ot recommended in clinical applications since they are
nown for not being as robust as micro-LC. However in our
orkﬂow we used a nano-Chip/MS system which is known to
e more  versatile and reliable than regular nano-LC system.
irstly, we  performed an analytical validation to test the
peciﬁcity, reproducibility and repeatability of LC–MS/MS as
ell as determining its LOD, LOQ and linearity. We then com-
ared our results to the well characterized C-ELISA method to
uantify serum hepcidin-25 in human samples [10]. Despite
iscrepancies in the absolute values of hepcidin measured,
e showed a good correlation between these two methods
r2 = 0.96), thus validating our LC–MS/MS assay for accurate
easurement of hepcidin in human serum samples. Further-
ore,  we  underlined the relevance of this measurement in
ron-deﬁciency anemia, anemia of inﬂammation and other
ron-related diseases. 3 ( 2 0 1 4 ) 60–67 61
2.  Materials  and  methods
2.1.  Chemicals  used
Trichloroacetic acid (TCA), ref. T9159-250G (Sigma–Aldrich);
Water ULC–MS, ref. 23214102, formic acid ULC–MS (FA)
ref. 069141A8,  acetonitrile ULC–MS (ACN) ref. 01204101 all
from Biosolve (Dieuze, France); Normal Goat serum, ref. S-
1000 Clinisciences (Nanterre, France); Protein LoBind tube
1.5 mL,  ref. 022431081 Eppendorf (Le Pecq, France); glass
vial insert ref. 5181–1270 and ProtID-Chip-43 II ref. G4240-
62005 both from Agilent Technologies (Santa Clara, CA, USA).
Human hepcidin standard (DTHFPICIFCCGCCHRSKCGMCCKT)
and internal hepcidin standard (DTHFPICIFCCGCCHRSKCGM-
CCKT) [13C6, 15N4] Arg16 were purchased from Eurogentec
(Seraing, Belgium) with a purity >97% assessed by RP-HPLC
and mass spectrometry. Standard peptides were synthetized
in lyophilized form with the same amino acid sequence (25 AA)
and folding (4 disulﬁte bridges Cys 7–23; 10–13; 11–19; 14–22)
as the endogenous human hepcidin-25.
2.2.  Human  samples  and  ELISA  determination  of
hepcidin
In France, since hepcidin is already an accepted serum ana-
lyte used in clinical settings, which is determined using mass
spectrometry or validated competitive C-ELISA [10], there was
no need for a speciﬁc authorization from an Ethics committee
for this work. However, serum samples included in this study
were part of a biobank (ofﬁcial registration # DC-2008-417) and
all patients signed an informed consent form to authorize the
use of their samples for research conducted in accordance
with the local Ethics committee.
2.3.  Liquid  chromatography  (LC)  separation
Nano-LC separation was carried out on a 1290 nano-LC system
(Agilent technologies). Peptides were loaded on a ProtID-
Chip-43 (Agilent technologies) containing a 43 mm  × 75 m
analytical column and a 40 nL trap-column packed with Zor-
bax 300SB-C18 5 m.  The mobile phase was composed of
H2O/ACN/FA (phase A 97:3:0.1, v/v/v and phase B 10:90:0.1,
v/v/v). The sample was loaded on the trapping column with
a ﬂow rate of 2.5 l/min using the capillary pump to deliver
an isocratic enrichment phase composed of 15% B. Further-
more, 7 l of ﬂush volume was used for cleaning the trapping
column from un-retained compound. The, trapped peptides
were separated from the analytical column using the nanop-
ump.  A 10-minute gradient was performed, starting with 3%
of solvent B and linearly ramped to 100% in 7 min. The column
was then washed for 2 min  and re-equilibrated during 1 min
with 97% of solvent A.
2.4.  Multiple  reaction  monitoring  analysisMass spectrometric detection was performed using a 6490
triple quadripole with a nano-ESI source operating in
positive mode and in SRM mode (Agilent technologies, Wald-
bronn, Germany). The control of the LC–MS/MS was done
o m i c s 3 ( 2 0 1 4 ) 60–67
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with MassHunter Software (Agilent technologies, Waldbronn,
Germany). The ESI nano spray was set-up according to the
following speciﬁcities: capillary tension 1700–2100 V, nebu-
lization gas ﬂow 11l/min and temperature at 150 ◦C. We
selected the most abundant ion detected after standard pep-
tide injection. Precursor ions followed were 559.4 m/z (z = 5) for
the endogenous Hepcidin and 560.6 m/z (z = 5) for the heavy
standard. Precursors ions were transferred inside the ﬁrst
quadrupole with an accelerator voltage of 4 V while ion funnel
RF high pressure was set to 180 V and low pressure to 80 V. Pre-
cursor ions were fragmented in “Product Ion Scan” mode and
the 5 most abundant generated fragments were selected to
constitute the SRM method (560.6 → 1045.5, 985, 766.7, 696.8,
646.2; 559.4 → 1045, 983, 764.6, 694.8, 645). Collision energies
(CE) were optimized as described in Table 1.
2.5.  Preparation  of  Hepcidin-25  standards
Lyophilized standards were resuspended at 200 ng/L with
H2O/ACN/FA (66.2:33.8:0.1, v/v/v). The solution was then sep-
arated into aliquots of 50 L in LoBind tubes and stored at
−80 ◦C. The internal standard was prepared at 5 ng/L using
the same protocol. Isotopically-labeled hepcidin was cho-
sen as the internal standard because of its physicochemical
properties which are similar to hepcidin. Both compounds
exhibited the same behavior during the preparation and chro-
matographic process while the mass difference of 10 amu,
provided by the heavy aa of the internal standard, permitted
the independent detection of each compound.
Appropriate dilutions of 200 ng/L hepcidin stock solutions
(0.125, 1.25, 25 g/mL) were made with H2O/ACN/FA (79:20:1,
v/v/v) to prepare the matrix-based calibration curve (normal
goat serum) at the concentration range of 0–200 ng/mL (0, 5, 10,
20, 50, 100, 200 ng/mL). The internal standard was spiked in the
model matrix and biological sample at a ﬁnal concentration of
100 ng/mL (Table 2).
2.6.  Hepcidin-25  pre-fractionation  protocol
All experiments were performed at 4 ◦C. In a 1.5 mL  LoBind
tube, 50 L of serum sample was mixed with 1 L of internal
hepcidin standard solution (5 ng/L), vortexed 10 s and then
1:1 ratio of 4% trichloroacetic acid (TCA) solution was added.
Samples were then vortexed a few seconds and centrifuged at
17,000 × g during 5 minutes to obtain a clear supernatant, fol-
lowed by a new centrifugation step at 17,000 × g during 5 min
after thawing on ice. The supernatant was transferred into a
new LoBind tube and dried in a vacuum concentrator (Lab-
conco, Kansas city, USA). The samples were resuspended with
10 L of H2O/ACN/FA (20:1:79, v/v/v) and vortexed at 1000 rpm
for 10 min. The LC vial was then centrifuged 3 min at 17,000 × g
at room temperature before transferring the sample and mak-
ing sample preparations in duplicates.
2.7.  Method  validationTo validate this method we evaluated speciﬁcity, linearity,
LOD, LOQ, precision and accuracy. Speciﬁcity was assessed by
conﬁrming that there were no interference peaks at the same
retention time than those of the analytes in the blank sample.
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Table 2 – Appropriate dilutions of light and heavy hepcidin stock solutions to prepare the calibration curve using model
matrix (Normal Goat serum) in the concentration range of 0 to 200 ng/mL (0, 5, 10, 20, 50, 100, 200 ng/mL). Internal
standard (Heavy hepcidin) was spiked in the model matrix and in the biological sample at a ﬁnal concentration of
100 ng/mL.
Normal goat serum Heavy hepcidin Light hepcidin
Volume (L) Volume (L) Initial concentration
(ng/L)
Final concentration
(ng/mL)
Volume (L) Initial
concentration
(ng/L)
Final
concentration
(ng/mL)
50
1
5
100  0
0.125
0
1 100 2 5
1 100 4 10
1 100 0.8 20
100 
100 
100 
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n order to do this, a 0 ng/mL point was added to the calibra-
ion curve and the software took it into account for computing
t. Calibration curves were constructed over the 0–200 ng/mL
ange. Intra-assay precision and accuracy were evaluated by
nalyzing the replicates of the calibration curve on the same
ay. Inter-assay precision and accuracy were assessed by ana-
yzing the same quality control (QC) samples on series of
nalyses performed on different days. The LOD has been
etermined using the signal obtained with the replicates at
00 ng/mL. S/N average obtained was of 148. LOD is calculated
ased on S/N = 3. LOD of 2 ng/mL was obtained. LOQ was deter-
ined in the same way but using S/N = 10. LOQ of 6 ng/mL was
btained. Accuracy was calculated using the Agilent software
Masshunter Quantitative analysis) based on the calibration
urve equation. Formula used was “Accuracy = [(calculated
oncentration)/(expected concentration)] × 100”.
.8.  Data  treatment  and  statistics
e  used the MassHunter Quantitative Analysis software (Agi-
ent technologies) to conduct bioinformatics data treatment.
ll replicate results for the calibration curve were loaded into
he software database. An automatic quantiﬁcation method
as used to treat all data in order to obtain the equation curve
ith the best ﬁt for the experimental points. The two transi-
ions 559.4 → 694.8 (light hepcidin) and 560.6 → 696.8 (heavy
epcidin) were used as quantiﬁers and were automatically
etected on speciﬁc retention time windows. Other transitions
ere used as qualiﬁers. Statistical analyses were performed
ith the MedCalc software (7.3). Unless indicated, we used
on-parametric tests (Kruskal–Wallis) to compute all available
ata. We  also used the Bland and Altman plot [11] and Dem-
ng adjusted regression curves [12] to test the commutability
f the methods.
.  Results  and  discussion
.1.  Pre-fractionation  optimizationn order to measure the hepcidin-25 level using LC-SRM
ethod, we  adapted the pre-fractionation protocol from
urao  et al. [13]. Based on protein precipitation, this method
s fast, simple, reproducible, cost-effective and overall very1.25
2 50
4 100
8 200
adapted to a routine clinical environment. TCA precipitation
showed a sufﬁcient recovery for peptides with a molecular
weight under 3 kDa, and allowed a direct injection of the
sample without evaporation or dilution. With this sample
preparation, we were able to detect 5 times more  hepcidin-25
than with direct analysis (not shown), probably due to sam-
ple simpliﬁcation and consequently matrix effect reduction.
On a serum sample, the reproducibility test was calculated
using an area ratio endogeneous hepcidin/heavy hepcidin and
it showed a coefﬁcient of variation of 1.5% (see below).
3.2.  LC-SRM  method  optimization
Firstly, transmission of ion precursor through the triple
quadrupole was optimized. For this purpose, cell accelerator
voltage (CAV) and RF of ion funnel were optimized to increase
ion transmission inside the Q1. Optimum CAV and ion funnel
RF enabled a gain of signal with respectively 49% and 30% com-
pared to reference values. The CAV optimum value was found
at 4 V (reference 7 V) and the ion funnel RF at 180–80 V (refer-
ence 210–110 V). Then 1 L of 10 g/mL solution hepdidin-25
standards (light and heavy) were injected to determine the
most abundant ion detected in “full-scan mode” for the light
and heavy standards (Fig. 1A). The mass spectra showed a
similar series of ions, mainly the quadruply, quintuply and
sextuply charged molecular ions for both standards. A highest
S/N were found at m/z 559.4 (M + 5H]5+) for the light standard
ions and at 560.6 m/z (M + 5 H]5+) for the heavy standard ions.
Precursor ions were fragmented in “product ion scan” mode to
observe the subsequent generated fragments. Five transitions
per peptide were followed and two transitions 559.4 → 694.8
(light hepcidin) and 560.6 → 696.8 (heavy hepcidin) were used
as quantiﬁers (higher S/N ratio). The sequence of the pep-
tides chosen was located in the unfolded N termini area of
the protein sequence (y19 to y23 ions with a mix  of charge
states) (Fig. 1B). Accordingly, the SRM method was optimized
for the collision energy (CE) transition by transition. This step
was performed automatically with “Peptide Optimizer” soft-
ware using a ramping CE in order to ﬁnd the optimum. CE was
a predominant parameter for the optimization, with an SRM
Signal enhancement of up to 6-fold compared to the method
of reference.
Optimum conditions were achieved by re-suspending sam-
ples in 20% acetonitrile/1% formic acid/79% water and storing
64  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 60–67
Fig. 1 – (A) Light hepdidin-25 standard chromatograms obtained by nano-HPLC–MS in “full-scan mode” showing quadruply,
pect
 N te
quintuply and sextuply charged molecular ions. (B) MS/MS  s
In red, the peptide fragment chosen located in the unfolded
the sample in a LC glass vial. The samples were then loaded
with 15% of B phase (90% CAN, 0.1% FA) at 2.5 l/min ﬂow
rate using the capillary pump. This increased the signal/noise
ratio about 30-fold probably due to a reduction of nonspeciﬁc
interactions between proteins and surfaces, and a reduction
in sample complexity linked to the fact that in this situ-
ation a number of hydrophilic peptides were eluted before
the analysis. To clean the trapping column from un-retained
compound we  used 7 l of ﬂush volume as well as a 10-min
chromatographic separation gradient starting with 3% of sol-
vent B and linearly ramped to 100% in 7 min. The column
was then washed for 2 min  and re-equilibrated for 1 min  with
97% of solvent A. Under these conditions, elution time of the
hepcidin-25 peptide was 3 min  (65% phase B).
3.3.  Analytical  validation  and  quantitation
The speciﬁcity of the method was evaluated by validating
the absence of interference peaks in blank sample at the
retention time of the analytes (0 ng/mL of hepcidin-25 in
normal goat serum). This blank sample was integrated by
the Mass Hunter software into the calibration curve per-
formed using a model matrix (normal goat serum) free of
hepcidin-25. Calibration curves were constructed over thera of the [M + 5 H]5+ precursor of light hepdidin-25 standard.
rmini area of the protein sequence (y19 to y23 ions).
0–200 ng/mL range based on hepcidin values found with the
orthogonal analysis method. The equation was linear when
ignoring origin and weighted 1/y.  r2 was obtained with the fol-
lowing equation y = 1.54636 + 0.02970 and was equal to 0.9665
(Fig. 2B). Finally, the quantitation of hepcidin-25 in cohort sam-
ples did not exceed 140 ng/mL therefore the calibration curve
(0–200 ng/mL) is perfectly suitable for dosage.
Each LC-SRM dosage was performed in duplicate in order to
calculate a coefﬁcient of variation. Intra-assay precision and
accuracy were assessed by analyzing four replicates of the cali-
bration curve point on the same day. Intra-assay precision was
around 7% for the 50 ng/mL point and 28% for the lowest con-
centration point (5 ng/mL). Intra-assay accuracy was close to
100% for the 20, 50, 100 and 200 ng/mL points and around 80%
for the lowest concentration points (5 and 10 ng/mL) (Table 3).
In order to evaluate inter-assay precision and accuracy, we
chose 2 points on the calibration curve (50 and 200 ng/mL) as
quality control (QC) samples which were analyzed on four sep-
arate days. Inter-assay precision was around 9–10%, accuracy
was close to 80% for the two QCs and LOD was determined
using the signal obtained with the replicates at 100 ng/mL. S/N
average obtained was 148. LOD is calculated based on S/N = 3.
LOD of 2 ng/mL was obtained. LOQ was determined in the
same way but using S/N = 10. LOQ of 6 ng/mL was obtained.
e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 60–67 65
Fig. 2 – (A) Workﬂow for nano-HPLC–MS quantiﬁcation of hepdidin-25 in human serum samples. (B) Calibration curves of
hepdidin-25 using model matrix (normal goat serum) in the concentration range of 0–200 ng/mL (0, 5, 10, 20, 50, 100,
2 nd w
y
H
i
a
m
3
f
A
h
G
w
M00 ng/mL). The equation was linear when ignoring origin a
 = 1.054636 + 0.029760, was equal to 0.9665.
owever, one cannot exclude that, in some human samples,
nterfering compounds could affect the precision of the assay,
nd additional validation to comply with the ISO 15189 norm
ight be needed.
.4.  Comparison  of  LC-SRM  and  C-ELISA  approaches
or hepcidin  quantitation
mong the different methods used to quantify bioactive
epcidin-25 in serum, the competitive C-ELISA developed by
anz et al. in 2008 [10] is a very valuable method that correlates
ell with a speciﬁc weak cation exchange (WCX) time-of-ﬂight
S assay [1]. We  further analyzed serum samples previously
Table 3 – Intra-assay coefﬁcient of variation and
accuracy (%).
Light concentration
(pg/L)
Intra-assay
CV (%)
Intra-assay
precision
accuracy (%)
5 28 24
10 21 18
20 8 6
50 7 3
100 17 0
200 13 9eighted 1/y. r2, obtained with the following equation
measured with this C-ELISA method using our MS protocol
(Fig. 3A). We  found a signiﬁcant positive correlation (r2 = 0.96,
Pearson’s r P < 0.001) and the Bland–Altman plot (Fig. 3B) vali-
dated the commutability of these methods. However, the slope
of the linear correlation (5.0255x) indicated that our assay pro-
vided values, which were ﬁve times lower than those obtained
with the C-ELISA. This result is likely related to the fact that
MS  methods are fully speciﬁc (i.e. only the 25aa isoform is
quantiﬁed) and to the difference in origin and purity of the
material used for the standard curves. Furthermore, the LC-
SRM CV for the 30 patients in our study was 9% compared to
5–19% in the study previously described by Ganz et al. In addi-
tion, our LOD is 2 ng/mL compared with a LOD at 5.5 ng/mL
for the reference C-ELISA method. Finally, our method shows
reproducibility under 10%, compared to the reproducibility of
C-ELISA which rises to 12%. Thus, our experimental results
underline the robustness and reliability of our quantitative
assay for hepcidin-25, as well as its suitability for the relevant
evaluation of hepcidin-25 in human serum within a clinical
environment.
As expected, hepcidin-25 levels differed for patients
suffering from iron deﬁciency (mean value of 29.87 ng/mL
or 49.97 ng/mL for patients with ferritin < 300 ng/mL and
>300 ng/mL, respectively) and our results show an appropri-
ate correlation between hepcidin and ferritin (r2 = 0.38 or by
splitting into 2 groups, r2 = 0.42 and 0.74 for patients with
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Fig. 3 – (A) Comparison of hepcidin-25 concentrations measured in serum samples from patient using nano HPLC–MS and
ELISA. A signiﬁcant positive correlation was obtained (r2 = 0.96, Pearson product-moment correlation coefﬁcient (Pearson’s r)
P < 0.001). (B) Commutability of the methods (ELISA and SRM) using a Bland–Altman plot. The Deming adjusted regression
curve equation is: y = 11,7691 + 4,9683x. (C) Proposed patient stratiﬁcation scheme for biochemical discrimination of iron
y (nodeﬁciency versus inﬂammatory status as set up in this assa
modify this value).
ferritin < 300 ng/mL and >300 ng/mL, respectively), thus
reﬂecting the regulation of both proteins by iron stores.
Moreover, hepcidin values also differed in patients with an
inﬂammatory status (mean value of 4.64 ng/mL for patients
with CRP < 10 mg/dL, vs. mean value of 55.85 ng/mL for
patients with CRP > 10 mg/dL). The values of hepcidin in our
cohort were distributed between 10 and 100 ng/mL. Though,
this assay allows biochemical discrimination of iron deﬁ-
ciency status and inﬂammatory status of patients as proposed
in the decision tree illustrated in Fig. 3C based on the article
by Sasu et al. [14].
4.  Conclusion
These past 10 years, numerous assays relying on immuno-
chemical and mass spectrometry methods have been
developed and described to measure hepcidin in human sam-
ples of blood and urine. The experimental method described
in the present work matches the appropriate standard for clin-
ical measurement of hepcidin-25 in human serum. Hepcidinte: the origin and purity of the standard material may
levels obtained differed from a reference C-ELISA assay which
validated the need for a calibrator mimicking human serum
and establishing a consensus on calibrator levels. This method
also has the ability to detect the truncated 20, 22 and 24-aa
isoforms of hepcidin (not shown) even though the relevance
of these isoforms for clinical applications still needs to be
established [15]. More importantly, our method relies on sim-
ple, robust, reproducible and straightforward cost-effective
pre-analytical steps that are speciﬁcally adapted to a clinical
environment, thus avoiding the need of solid phase extrac-
tion for example. In conclusion, our approach is compatible
with routine hepcidin measurements in daily clinical practice
and for discriminating between iron-deﬁciency anemia and
anemia of chronic disease.
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